Index
By TNW
About Index
Trending news
Analyze
Pricing
Sign up or sign in
bluebird bio
Work at bluebird bio?
Add yourself to this profile
2936
bluebird bio
bluebird bio is developing innovative gene therapies for severe genetic disorders. Our vision is to make the hope of gene therapy a reality.
Edit Profile
bluebirdbio.com
Technology
>
Biotechnology
B2c
Founded in
1992
Raised
$384.3M
More info
Elsewhere
Also headquartered in Cambridge
MIT
Raspberry Pi
ARM
Xconomy
Mobile.co
nuTonomy
HubSpot
Biogen
General Catalyst
Harvard University
Companies in the same industry
AgeneBio
Bioheart
Entelos
Morphogen-IX
LAM Therapeutics
Emerus Hospital Partners
GLO Science
InSite Vision
Molplex
Laurantis Pharma
Alexa global traffic share
Twitter followers
Overview
Funding
5
Add info
Latest funding
Show all
Post-IPO equity
$250,000,000
Venture capital
$9,300,000
California Institute for Regenerative Medicine
Employees
Team size
50+
Locations
HQ
Cambridge
,
United States
Headquarters
$250,000,000
Post-IPO equity
Twitter
Boston Business on Twitter
The Motley Fool
Better Buy: Agenus Inc. vs. bluebird bio
The Motley Fool
Why Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today
The Motley Fool
Better Buy: bluebird bio vs. Inovio Pharmaceuticals
The Motley Fool
Better Buy: Juno Therapeutics vs. bluebird bio
The Motley Fool
bluebird bio Inc: Catnapping in Cambridge
The Motley Fool
Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys
The Motley Fool
bluebird bio, Inc. Takes Flight Towards First Approval
The Motley Fool
Here's Why bluebird bio.'s Stock Tumbled in March
The Motley Fool
Why bluebird bio's Stock Jumped 12.9% on Wednesday
The Motley Fool
Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals
The Motley Fool
Why Bluebird Bio Inc. Plunged Today
The Motley Fool
Why bluebird bio Inc Presented a Lower Price Today
The Motley Fool
Why bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped Today
Stock markets
The Motley Fool
Why bluebird bio Inc.'s Stock Dropped 34% in January
Stock markets
The Motley Fool
bluebird bio Inc. Takes Flight
Stock markets
Health
The Motley Fool
Why Bluebird Bio Inc.'s Stock Bounced Back --
Stock markets
Health
The Motley Fool
Why bluebird bio Inc's Stock Is Tanking Today --
Stock markets
Health
The Motley Fool
Here's Why Bluebird Bio Turned in a Disappointing 2015 --
The Motley Fool
bluebird bio Inc: Gene Therapy Is (Still) Hard --
Health
Stock markets
MIT
Raspberry Pi
ARM
Xconomy
Mobile.co
nuTonomy
HubSpot
Biogen
General Catalyst
Harvard University
AgeneBio
Entelos
LAM Therapeutics
Molplex
Laurantis Pharma